TFO
BOLT icon

Tarbox Family Office’s Bolt Biotherapeutics BOLT Stock Holding History

Tarbox Family Office’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50
Closed -$15K – 1157
2021
Q2 		$15K Buy
+50
New +$20.3K ﹤0.01% 418

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Tarbox Family Office's BOLT Position: Q3 2021 in Review

Tarbox Family Office sold out of Bolt Biotherapeutics (BOLT) in Q3 2021, closing a stake of 50 shares — an estimated $15K sold.

Tarbox Family Office first reported a position in BOLT in Q2 2021 and held it in 1 quarter. The position peaked at $15K in Q2 2021. 71 funds tracked by Wall St. Rank hold BOLT as of Q3 2021.

  • Tarbox Family Office reported no remaining Bolt Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Tarbox Family Office sold 50 Bolt Biotherapeutics shares in Q3 2021, an estimated $15K.
  • Tarbox Family Office first reported a position in Bolt Biotherapeutics in Q2 2021 and held it in 1 quarter.
  • Tarbox Family Office's Bolt Biotherapeutics position peaked at $15K in Q2 2021.
  • 71 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2021.

Based on Tarbox Family Office's 13F filing for Q3 2021, filed 12 Oct 2021.